Compare VSAT & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | CNTA |
|---|---|---|
| Founded | 1986 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | 118 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.1B |
| IPO Year | 1996 | 2021 |
| Metric | VSAT | CNTA |
|---|---|---|
| Price | $63.85 | $39.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $51.40 | $42.00 |
| AVG Volume (30 Days) | 1.6M | ★ 5.0M |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.88 | 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | $5.34 | N/A |
| Revenue Next Year | $3.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.95 | $10.95 |
| 52 Week High | $64.46 | $40.26 |
| Indicator | VSAT | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 72.10 | 74.75 |
| Support Level | $42.18 | $39.16 |
| Resistance Level | N/A | $40.26 |
| Average True Range (ATR) | 3.59 | 0.32 |
| MACD | 1.11 | -0.10 |
| Stochastic Oscillator | 95.31 | 34.09 |
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.